Altimmune Operating Expenses 2010-2024 | ALT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Altimmune operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Altimmune operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.8B
Takeda Pharmaceutical (TAK)	$42.6B
Sandoz Group AG (SDZNY)	$19.5B
Merck (MKKGY)	$19.1B
Astellas Pharma (ALPMY)	$18.3B
United Therapeutics (UTHR)	$16.6B
Summit Therapeutics (SMMT)	$14B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$12B
Catalent (CTLT)	$11.1B
Madrigal Pharmaceuticals (MDGL)	$7.6B
Orion OYJ (ORINY)	$6.7B
Corcept Therapeutics (CORT)	$6B
Ionis Pharmaceuticals (IONS)	$5.4B
Crinetics Pharmaceuticals (CRNX)	$5.2B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Soleno Therapeutics (SLNO)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.2B
NewAmsterdam Pharma (NAMS)	$1.9B
Xencor (XNCR)	$1.8B
Recursion Pharmaceuticals (RXRX)	$1.6B
Evotec AG (EVO)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Harrow (HROW)	$1.5B
Indivior (INDV)	$1.5B
Guardian Pharmacy Services (GRDN)	$1.5B
Ocular Therapeutix (OCUL)	$1.4B